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Abstract
Hepatitis C virus is not cleared after primary infection in 50–85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the
early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-
related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been
reported during treatment of acute hepatitis C.
We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b
monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoimmunity by interferon, also for acute hepatitis,
and underlines the importance of a prompt diagnosis and a rapid discontinuation of interferon treatment for an improvement of clinical
outcomes.
© 2005 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Keywords: Acute hepatitis C; Hepatitis C virus; IFN; Polymyositis
1. Introduction
Hepatitis C virus (HCV) is not cleared after primary infec-
tion in 50–85% of subjects exposed to HCV [1–3], and
evolves to significant chronic liver disease in up to 30% of
subjects [4]. Recent meta-analyses [5–8] have clearly demon-
strated that treatment with standard alpha-interferon (IFN-)
during the early phase of infection significantly enhances the
likelihood of a sustained clearance of HCV. Available data
from the trials which specifically report on IFN-related side
effects and adverse events [9–13] suggest that the tolerabil-
ity of standard IFN in this context is good, and that side
effects are uncommon although occasionally treatment has to
be stopped. IFN is apparently tolerated by jaundiced patients
also. Immuno-mediated adverse reactions and the occasional
unmasking of autoimmune diseases have not been reported
during treatment of acute hepatitis C.
Pegylated IFNs (PEG-IFNs) -2a and -2b in combina-
tion to ribavirin [14,15] are currently considered the gold
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standard for chronic hepatitis C treatment, due to their more
favourable efficacy and safety profile. Autoimmune-like reac-
tions to PEG-IFNs in the pivotal trials have been equally
uncommon than in the standard IFN comparator arms [16].
Although all data on treatment of acute hepatitis C concern
the use of standard IFN, it is biologically and pharmacolog-
ically plausible that PEG-IFNs will be even more effective
and have a better subjective tolerability in these patients. As
a matter of fact, their off-label use for this indication has
already started in some countries.
We therefore feel useful to call the physician’s attention
to a patient recently observed at our Unit, who developed
acute HCV infection after cardiac catheterisation and, while
receiving PEG-IFN--2b monotherapy, developed a severe
polymyositis.
2. Case history
A 51-year-old Caucasic man, without any history of expo-
sure to drugs or toxins or significant alcohol abuse, was
admitted to our Unit in May 2002 because of a 2-month
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history of severe asthenia and proximal muscle weakness
associated to high values of alanine aminotransferase (ALT)
[>10 time upper limit of normal (uln)].
Ten months earlier, 40 days after a cardiac catheterisation
for chest pain which showed no coronary hearth disease,
he developed jaundice with ALT levels 20 × uln. He
was diagnosed as acute hepatitis C, since anti-HCV and
HCV-RNA were positive. HCV genotype tested at that time
was 1b. Anti-HCV had been negative, and ALT normal,
at the time of the catheterisation. HBsAg, anti-HBc IgM,
anti-HAV IgM, anti-EBV IgM, anti-CMV IgM, anti-HIV, as
well as creatinine phosphokinase levels, were and remained
negative throughout the clinical course.
The patient was initially seen at an Infectious Disease
Clinic and given treatment with PEG-IFN--2b 80g/week
s.c., starting on August 2001. Anti-nuclear and smooth mus-
cle antibodies tested negative before treatment. ALT came
into the normal range within 1 month, and serum HCV-
RNA was undetectable by PCR in January 2002. Treatment
was reasonably well tolerated up to February 2002, when
a de novo increase of ALT levels was found in association
with appearance of progressive generalised weakness. This
was considered to be a relapse of HCV, and therefore PEG-
IFN was stopped in April 2002. Since severe asthenia and
markedly raised ALT persisted, the patient was referred to
our Unit on May 2002.
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Fig. 1. Disruption of muscle fibres and the scattered inflammatory cells in
the interstitium.
Fig. 2. Pattern of ALT and CPK values and HCV-RNA during and after IFN
course.
with corticosteroids (metilprednisolone 1 mg/(kg die)) was
started. After 3 months of steroids therapy, the patient had
an improvement in subjective symptoms with decreases
until normalisation of level of CPK, LDH and ALT (Fig. 2).
HCV-RNA has remained persistently negative throughout
steroid treatment up to the last follow-up visit.
3. Discussion
Polymyositis is a systemic autoimmune disorder charac-
terised by proximal muscle weakness, which most frequently
involves the limbs, neck and trunk [17]. In the literature
there are some reports of HCV infection preceding or
coincident with polymyositis [18–23]. However, while the
association between HCV and mixed essential cryoglobu-
linemia, vasculitis, glomerulonephritis, autoimmune thyroidPhysical examination showed a reduction of muscle
trength, most evident in the proximal muscle girdle of
he upper limbs with a relative sparing of the lower limbs.
aboratory tests showed normal white blood cells and
latelets counts and a normal haemoglobin level. ESR
as mildly raised and C-reactive protein and renal func-
ion tests normal. Serum enzyme profile was abnormal
or AST (10 × uln), ALT (8 × uln), creatinine phosphoki-
ase (10.519 IU/l; N.R. < 460 IU/l) and lactic dehydrogenase
1385 IU/l; N.R. 130–460 IU/l). Serum HCV RNA was unde-
ectable (Amplicor Monitor, Roche).
Immunological investigations showed the presence of
nti-nuclear antibody positivity (‘speckled pattern’) with
itration of 1/80, with negative anti-extractable nuclear
ntigen antibodies (ENA), anti-neutrophil cytoplasmatic
ntibodies (ANCA) and anti-double stranded (DS) DNA anti-
odies. Anti-smooth muscle, mitochondrial and liver–kidney
icrosomal antibodies were negative. In spite of the pres-
nce of anti-peroxidase antibodies (TPO-ab) greater than
00 IU/ml (N.R. 0–34), thyroid function tests (T3, fT3, T4,
T4, TSH) were normal. HLA typing showed: A2, A32 (19),
7, B60 (40); DR11, open DR4, DR52, DQ (3).
An electromyography was performed and documented
brillations and polyphasic motor unit potentials of low
mplitude and short duration, suggestive of an inflammatory
uscle disease. A muscle biopsy of the right deltoid showed
n endomysial inflammatory infiltrate, degenerating and
egenerating fibres, areas of muscle fibre necrosis and
solated atrophy (Fig. 1). A diagnosis of polymyositis
econdary to PEG-IFN therapy was made, and treatment
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diseases is well established, the casual relationship with
other autoimmune diseases such as polymyositis is still
uncertain.
Few reports on development of polymyositis associated
with IFN therapy have been described as a complication
during treatment for malignancies or viral infections
(HCV, HBV) [23–32]. Although HCV itself might cause
polymyositis, it is unlikely that in our patient the disease
was virus-related considering the temporal sequence of
events. Our patient had no muscular symptoms in the initial
phase of viral infection, but polymyositis developed well
after starting IFN treatment at a time when HCV-RNA was
undetectable. Furthermore, when IFN was withdrawn and
steroid treatment instituted, there was a rapid improvement
of subjective symptoms with normalisation of CPK, LDH
and ALT. Ultimately, the detection of a typical EMG pattern
and of features of inflammation on muscle biopsy confirmed
the diagnosis of ‘classic’ polymyositis.
One word of caution should be paid for starting treat-
ment soon after the beginning of symptoms of acute hepatitis
C. According to Gerlach et al.’s paper [33] and a recent
meta-analysis [8], more than half of patients will completely
recover from acute HCV infection within 3 months from the
onset of symptoms and therefore the anti-viral therapy could
be further delayed without any relevant consequences on pro-
gression to chronicity.
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